CRL
HealthcareCharles River Laboratories International, Inc.
Key Drivers
- Margin rebound
- Strong cash flow
- Elevated leverage
AIAI Summary
CRL now looks like a real stabilization story rather than a broken recovery, with improving margins, positive organic growth, and raised free-cash-flow guidance, but after the sharp rerating the key question is whether demand can keep compounding fast enough to justify the valuation given higher leverage and still-muted reported revenue.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin rebound
- •Strong cash flow
- •Elevated leverage
CRL delivered a sharp margin and cash-flow rebound, but elevated leverage, heavy intangibles, and a rich valuation limit the upside.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Stretch risk
- •Support hold
CRL has been in a strong uptrend over the last month, but after a sharp ~25% run it looks stretched and should hold $260–$265 to keep the bullish setup intact.
Sharp ~25% rally in three weeks with a recent pullback from $284.37 to $280.05 suggests short-term profit-taking risk
Sentiment & News
Key News Insights:
- •Q2 beat
- •Raised guidance
- •Demand recovery
Charles River Laboratories beat Q2 estimates, raised full-year guidance, and hit a 52-week high as demand improved, though the biopharma recovery remains gradual.
The latest results and upbeat guidance are supportive for CRL's near-term momentum, but sustained upside will depend on a broader and more durable demand rebound
Similar Companies in Healthcare
Other companies in the same sector with AI ratings